OVULEN-21 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ovulen-21, and what generic alternatives are available?
Ovulen-21 is a drug marketed by Gd Searle Llc and is included in one NDA.
The generic ingredient in OVULEN-21 is ethynodiol diacetate; mestranol. There are four drug master file entries for this compound. Additional details are available on the ethynodiol diacetate; mestranol profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OVULEN-21?
- What are the global sales for OVULEN-21?
- What is Average Wholesale Price for OVULEN-21?
Summary for OVULEN-21
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 85 |
| Patent Applications: | 3,896 |
| DailyMed Link: | OVULEN-21 at DailyMed |
US Patents and Regulatory Information for OVULEN-21
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gd Searle Llc | OVULEN-21 | ethynodiol diacetate; mestranol | TABLET;ORAL-21 | 016029-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
